Announcements Trials
Browse Landscape

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Malnutrition 2

Interventions

Flow Cytometry 36Gene Expression Profiling 34Surveys and Questionnaires 27Polymerase Chain Reaction 24Microarray Analysis 23Blood Specimen Collection 19Interviews as Topic 18Imatinib Mesylate 15Amplified Fragment Length Polymorphism Analysis 14Reverse Transcriptase Polymerase Chain Reaction 13Cytogenetic Analysis 13Rituximab 12venetoclax 11nilotinib 10Psychiatric Rehabilitation 10Dasatinib 10Immunologic Techniques 9DNA Methylation 9Blotting, Western 9ponatinib 8Watchful Waiting 8Observation 8In Situ Hybridization, Fluorescence 8Base Sequence 8Azacitidine 8ibrutinib 7fludarabine 7bosutinib 7Therapeutics 7Specimen Handling 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × fish oil triglycerides × Other hematologic neoplasm × Clear all
NCT06274788 2025-09-05

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Fresenius Kabi

Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04807478 2022-08-04

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Fresenius Kabi

Withdrawn
LymphoidOther hematologic neoplasm

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡